Comparison of intravitreal ranibizumab and bevacizumab for the treatment of macular edema secondary to retinal vein occlusion

International Journal of Ophthalmology

Volumn 7, Issue 1, 2013, Pages 86-91

  Yuan, Alex ^a   Ahmad, Baseer U ^b   Xu, David ^a   Singh, Rishi P ^a   Kaiser, Peter K ^a   Martin, Daniel F ^a   Sears, Jonathan E ^a   Schachat, Andrew P ^a   Ehlers, Justis P ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

^b Retina Institute   (United States)

Author keywords

Bevacizumab; Macular edema; Optical coherence tomography; Ranibizumab; Retinal vein occlusion

Indexed keywords

EID: 84896442277     PISSN: 22223959     EISSN: 22274898     Source Type: Journal    
DOI: 10.3980/j.issn.2222-3959.2014.01.15     Document Type: Article

References (25)

1. Klein R, Moss SE, Meuer SM, Klein BE. The 15-year cumulative incidence of retinal vein occlusion: the beaver dam eye study. Arch Ophthalmol. 2008;126(4):513-518. [PubMed]
2. The Branch Vein Occlusion Study Group Argon laser photocoagulation for macular edema in branch vein occlusion. Am J Ophthalmol. 1984;98(3):271-282. [PubMed]
3. The Central Vein Occlusion Study Group M Report Evaluation of grid pattern photocoagulation for macular edema in central vein occlusion. Ophthalmology. 1995;102(10):1425-1433. [PubMed]
4. Scott IU, Ip MS, VanVeldhuisen PC, Oden NL, Blodi BA, Fisher M, Chan CK, Gonzalez VH, Singerman LJ, Tolentino M, SCORE Study Research Group A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with standard care to treat vision loss associated with macular edema secondary to branch retinal vein occlusion: the standard care vs corticosteroid for retinal vein occlusion (SCORE) study report 6. Arch Ophthalmol. 2009;127(9):1115-1128. [PMC free article] [PubMed]
5. Haller JA, Bandello F, Belfort R, Jr, Blumenkranz MS, Gillies M, Heier J, Loewenstein A, Yoon Y H, Jacques ML, Jiao J, Li XY, Whitcup SM, OZURDEX GENEVA Study Group Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion. Ophthalmology 2010;117(6) 2010;117(6):1134, 1146.e3. [PubMed]
6. Ip MS, Scott IU, VanVeldhuisen PC, Oden NL, Blodi BA, Fisher M, Singerman LJ, Tolentino M, Chan CK, Gonzalez VH, SCORE Study Research Group A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with observation to treat vision loss associated with macular edema secondary to central retinal vein occlusion: the standard care vs corticosteroid for retinal vein occlusion (SCORE) study report 5. Arch Ophthalmol. 2009;127(9):1101-1114. [PMC free article] [PubMed]
7. Brown DM, Campochiaro PA, Bhisitkul RB, Ho AC, Gray S, Saroj N, Adamis AP, Rubio RG, Murahashi WY. Sustained benefits from ranibizumab for macular edema following branch retinal vein occlusion: 12-month outcomes of a phase III study. Ophthalmology. 2011;118(8):1594-1602. [PubMed]
8. Campochiaro PA, Brown DM, Awh CC, Lee SY, Gray S, Saroj N, Murahashi WY, Rubio RG. Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: Twelve-month outcomes of a phase III study. Ophthalmology. 2011;118(10):2041-2049. [PubMed]
9. Spaide RF, Chang LK, Klancnik JM, Yannuzzi LA, Sorenson J, Slakter JS, Freund KB, Klein R. Prospective study of intravitreal ranibizumab as a treatment for decreased visual acuity secondary to central retinal vein occlusion. Am J Ophthalmol. 2009;147(2):298-306. [PubMed]
10. Pieramici DJ, Rabena M, Castellarin AA, Nasir M, See R, Norton T, Sanchez A, Risard S, Avery RL. Ranibizumab for the treatment of macular edema associated with perfused central retinal vein occlusions. Ophthalmology. 2008;115(10) :e47-54.
11. Figueroa MS, Contreras I, Noval S, Arruabarrena C. Results of bevacizumab as the primary treatment for retinal vein occlusions. Br J Ophthalmol. 2010;94(8):1052-1056. [PubMed]
12. Gregori NZ, Rattan GH, Rosenfeld PJ, Puliafito CA, Feuer W, Flynn HW, Jr, Berrocal AM, Al-Attar L, Dubovy S, Smiddy WE, Schwartz SG, Lee WH, Murray TG. Safety and efficacy of intravitreal bevacizumab (avastin) for the management of branch and hemiretinal vein occlusion. Retina. 2009;29(7):913-925. [PubMed]
13. Jaissle GB, Leitritz M, Gelisken F, Ziemssen F, Bartz-Schmidt KU, Szurman P. One-year results after intravitreal bevacizumab therapy for macular edema secondary to branch retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol. 2009;247(1):27-33. [PubMed]
14. Wu L, Arevalo JF, Roca JA, Maia M, Berrocal MH, Rodriguez FJ, Evans T, Costa RA, Cardillo J, Pan-American Collaborative Retina Study Group (PACORES) Comparison of two doses of intravitreal bevacizumab (avastin) for treatment of macular edema secondary to branch retinal vein occlusion: Results from the pan-american collaborative retina study group at 6 months of follow-up. Retina. 2008;28(2):212-219. [PubMed]
15. Costa RA, Jorge R, Calucci D, Melo LA, Jr, Cardillo JA, Scott IU. Intravitreal bevacizumab (avastin) for central and hemicentral retinal vein occlusions: IBeVO study. Retina. 2007;27(2):141-149. [PubMed]
16. CATT Research Group. Martin DF, Maguire MG, Ying GS, Grunwald JE, Fine SL, Jaffe GJ. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med. 2011;364(20):1897-1908. [PMC free article] [PubMed]
17. Martin DF, Maguire MG, Fine SL, Ying GS, Jaffe GJ, Grunwald JE, Toth C, Redford M, Ferris FL, 3rd, Comparison f Age-related Macular Degeneration Treatments Trials (CATT) Research Group Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology. 2012;119(7):1388-1398. [PMC free article] [PubMed]
18. Boyer D, Heier J, Brown DM, Clark WL, Vitti R, Berliner AJ, Groetzbach G, Zeitz O, Sandbrink R, Zhu X, Beckmann K, Haller JA. Vascular endothelial growth factor trap-eye for macular edema secondary to central retinal vein occlusion: Six-month results of the phase 3 COPERNICUS study. Ophthalmology. 2012;119(5):1024-1032. [PubMed]
19. Bakri SJ, Snyder MR, Reid JM, Pulido JS, Ezzat MK, Singh RJ. Pharmacokinetics of intravitreal ranibizumab (lucentis) Ophthalmology. 2007;114(12):2179-2182. [PubMed]
20. Bakri SJ, Snyder MR, Reid JM, Pulido JS, Singh RJ. Pharmacokinetics of intravitreal bevacizumab (avastin) Ophthalmology. 2007;114(5):855-859. [PubMed]
21. Gaudreault J, Fei D, Rusit J, Suboc P, Shiu V. Preclinical pharmacokinetics of ranibizumab (rhuFabV2) after a single intravitreal administration. Invest Ophthalmol Vis Sci. 2005;46(2):726-733. [PubMed]
22. Zhu Q, Ziemssen F, Henke-Fahle S, Tatar O, Szurman P, Aisenbrey S, Schneiderhan-Marra N, Xu X, Tubingen Bevacizumab Study Group. Grisanti S. Vitreous levels of bevacizumab and vascular endothelial growth factor-A in patients with choroidal neovascularization. Ophthalmology. 2008;115(10):1750- 1755, 1755.e1. [PubMed]
23. Suzuki Y, Nakazawa M, Suzuki K, Yamazaki H, Miyagawa Y. Expression profiles of cytokines and chemokines in vitreous fluid in diabetic retinopathy and central retinal vein occlusion. Jpn J Ophthalmol. 2011;55(3):256-263. [PubMed]
24. Aiello LP, Avery RL, Arrigg PG, Keyt BA, Jampel HD, Shah ST, Pasquale LR, Thieme H, Iwamoto MA, Park JE. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med. 1994;331(22):1480-1487. [PubMed]
25. Karagiannis DA, Karampelas MD, Soumplis VM, Amariotakis C, Georgalas I, Kandarakis A. Recurrenceofmacular edem a in retinal vein occlusions after treatm ent with in travitreal ranibizumab (lucentis) Can J Ophthalmol. 2011;46(6):486-490.[PubMed]